Publicacións nas que colabora con Isaac Alonso García (12)
2024
-
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions
International Journal of Antimicrobial Agents, Vol. 63, Núm. 5
-
Corrigendum to “Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions” [International Journal of Antimicrobial Agents Volume 63, Issue 5 (2024) 107150] (International Journal of Antimicrobial Agents (2024) 63(5), (S0924857924000682), (10.1016/j.ijantimicag.2024.107150))
International Journal of Antimicrobial Agents
-
Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study
Eurosurveillance, Vol. 29, Núm. 15
2023
-
Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain
International Journal of Antimicrobial Agents, Vol. 61, Núm. 4
-
Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-β-Lactamase VIM-1
Antimicrobial agents and chemotherapy, Vol. 67, Núm. 5, pp. e0150522
-
In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification
International Journal of Antimicrobial Agents, Vol. 62, Núm. 4
-
Interplay between OXA-10 β-Lactamase Production and Low Outer-Membrane Permeability in Carbapenem Resistance in Enterobacterales
Antibiotics, Vol. 12, Núm. 6
-
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 5, pp. 1195-1200
2022
-
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa
The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815
-
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales
Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2
-
Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum b-Lactamase-Producing Enterobacterales"
Antimicrobial Agents and Chemotherapy
-
Selection of AmpC β-Lactamase Variants and Metalloβ- Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/ XDR Pseudomonas aeruginosa Infections
Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2